Product Description
ICP-488 is a small molecule binder of the pseudokinase domain (Janus Homology 2 or JH2) of TYK2, which is developed for the treatment of inflammatory diseases such as psoriasis and IBD. (Sourced from: https://cn.innocarepharma.com/en/media/press-release/20210326/)
Mechanisms of Action: Allosteric TYK2 Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Company: Innocare Pharma
Company Location: Asia Pacific
Company Founding Year: 2015
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: China
Active Clinical Trial Count: 7
Recent & Upcoming Milestones
- Clinical Outcomes Reported - InnoCare Pharma presented P3 Psoriasis results on 2026-07-27 for ICP-488
Highest Development Phases
Phase 3: Psoriasis
Phase 2: Lupus Erythematosus, Cutaneous|Other
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT07440537 |
ICP-CL-01008 | P2 |
Recruiting |
Lupus Erythematosus, Cutaneous |
2027-03-01 |
12% |
2026-06-10 |
|
NCT06842199 |
ICP-CL-01005 | P3 |
Recruiting |
Psoriasis |
2026-05-01 |
11% |
2026-02-10 |
Patient Enrollment|Primary Endpoints|Treatments |
NCT07727486 |
pSjS | P2 |
Not yet recruiting |
Other |
2028-12-01 |
61% |
2026-07-28 |
|
CTR20250582 |
CTR20250582 | P3 |
Active, not recruiting |
Psoriasis |
None |
2026-02-15 |
Patient Enrollment|Treatments|Trial Status |
|
CTR20232558 |
CTR20232558 | P2 |
Completed |
Psoriasis |
2024-09-18 |
2025-04-29 |
Patient Enrollment|Primary Completion Date|Start Date|Study Completion Date|Treatments|Trial Status |
|
CTR20221471 |
CTR20221471 | P1 |
Recruiting |
Psoriasis |
None |
2025-04-29 |
Patient Enrollment|Treatments |
|
NCT06109818 |
ICP-CL-01002 | P2 |
Completed |
Psoriasis |
2024-08-05 |
2025-03-01 |
Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments|Trial Status |
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
12/23/2025 |
News Article |
InnoCare Announces NMPA Approval of a Phase II Clinical Trial of TYK2 Inhibitor ICP-488 for Cutaneous Lupus Erythematosus |
|
08/19/2025 |
News Article |
InnoCare Releases 2025 Interim Results and Business Highlights |
|
03/27/2025 |
News Article |
InnoCare Releases 2024 Results and Business Highlights |
|
03/20/2025 |
News Article |
InnoCare Announces First Patient Dosed in the Phase III Registrational Trial of ICP-488 for the Treatment of Psoriasis in China |